EPO and chronic kidney disease: Peginesatide (formerly known as HematideTM) is a synthetic, PEGylated, investigational, peptide-based ESA that has an amino acid sequence unrelated to endogenous EPO (Fan et al. 2006) and is currently being developed in the United States for the treatment of anemia due to CKD in patients on dialysis.